Class I BCS based biowaiver with different amounts of API between T and R [Dissolution / BCS / IVIVC]

posted by joosefupas – Italy, 2018-11-08 12:00 (2359 d 05:16 ago) – Posting: # 19548
Views: 4,098

Hello everyone,

I have already googled around the web but couldn't find any answers thus I'll see if anyone can help here!

ICH M9 draft guidance states that “BCS-based biowaivers are applicable to drug products where the drug substance(s) (thus APIs) in test and reference products are identical (e.g. same salt, ester, isomer or mixture of isomers from that in the reference product).

My question now is, what about different API doses/amount between test and reference though?
More specifically our test product contains the exact double amount of APIs (both BCS Class I drugs) of the reference product (1000/130mg of paracetamol/caffeine TEST vs 500/65mg REFERENCE).

Given the API amount difference between T and R do you think a BCS based biowaiver application would still be applicable?

Thanks a lot in advance for the great support

Joosé

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
21 visitors (0 registered, 21 guests [including 4 identified bots]).
Forum time: 18:16 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5